Anti-Apolipoprotein A I antibody [1409] (ab20918)

Overview

  • Product nameAnti-Apolipoprotein A I antibody [1409]
    See all Apolipoprotein A I primary antibodies
  • Description
    Mouse monoclonal [1409] to Apolipoprotein A I
  • Specificityab20918 does not cross-react with APO A II or Apo B.
  • Tested applicationsIHC-P, Sandwich ELISA, ELISA, RIA, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Full length native protein (purified) (Human plasma).

  • Positive control
    • This antibody gave a positive result in IHC in the following FFPE tissue: Human normal liver.

Properties

Applications

Our Abpromise guarantee covers the use of ab20918 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use a concentration of 1 µg/ml.
Sandwich ELISA Use a concentration of 1 µg/ml. Can be paired for Sandwich ELISA with Rabbit polyclonal to Apolipoprotein A I (ab64308). For sandwich ELISA, use this antibody as Capture at 1µg/ml with ab64308 as Detection.
ELISA Use at an assay dependent dilution.
RIA Use at an assay dependent dilution.
ICC/IF Use a concentration of 1 ��g/ml.

Target

  • FunctionParticipates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.
  • Tissue specificityMajor protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine.
  • Involvement in diseaseDefects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
    Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
    Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed.
    Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.
  • Sequence similaritiesBelongs to the apolipoprotein A1/A4/E family.
  • Post-translational
    modifications
    Palmitoylated.
    Phosphorylation sites are present in the extracelllular medium.
  • Cellular localizationSecreted.
  • Information by UniProt
  • Database links
  • Alternative names
    • Apo AI antibody
    • Apo-AI antibody
    • ApoA I antibody
    • ApoA-I antibody
    • APOA1 antibody
    • APOA1/APOC3 fusion gene antibody
    • APOA1_HUMAN antibody
    • Apolipoprotein A I precursor antibody
    • Apolipoprotein A-I(1-242) antibody
    • Apolipoprotein A1 antibody
    • Apolipoprotein AI antibody
    • Apolipoprotein of high density lipoprotein antibody
    • ApolipoproteinAI antibody
    • Brp14 antibody
    • Ltw1 antibody
    • Lvtw1 antibody
    • MGC117399 antibody
    • Sep1 antibody
    • Sep2 antibody
    see all

Anti-Apolipoprotein A I antibody [1409] images

  • Standard Curve for Apolipoprotein A I (Analyte: ab50239) dilution range 1pg/ml to 1ug/ml using Capture Antibody Mouse monoclonal [1409] to Apolipoprotein A I (ab20918) at 1ug/ml and Detector Antibody Rabbit polyclonal to Apolipoprotein A I (ab64308) at 0.5ug/ml
  • ICC/IF image of ab20918 stained HepG2 cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab20918, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • IHC image of Apolipoprotein A I staining in Human normal liver formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab20918, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

Protocols

References for Anti-Apolipoprotein A I antibody [1409] (ab20918)

ab20918 has not yet been referenced specifically in any publications.

Product Wall

Thank you for contacting us. Yes, the Apolipoprotein A I protein ab90760 is the correct target for the antibodies ab52945 and ab20918. However, please note that the only data we have for sELISA are : - ab52945 has been used in sELISA in pair wi...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"